Testing an antibody-drug for advanced certain cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older.
- You have one of these advanced cancers: TNBC breast cancer, lung adenocarcinoma (NSCLC), endometrial cancer, or high-grade serous ovarian/fallopian tube/primary peritoneal cancer.
- Your cancer has gotten worse after prior treatment, and you’ve had limited lines of systemic cancer therapy (not many different treatments).
- Your tumor tissue sample can be tested for “FR-alpha” using a lab test (IHC); the sample must be usable for testing.
- Your overall health labs are acceptable: heart/liver/kidney function and bone marrow counts meet trial thresholds.
- You must be able to come off prior cancer medicines for the required washout time before starting this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug (LNF1901) for people with advanced cancers that haven't responded to standard treatments. The goal is to see if it is safe and how well it works, and it might help control the cancer or shrink tumors.
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.